CADL vs COR: fair value comparison
Candel Therapeutics, Inc. and Cencora, Inc. · Updated 2026-10-19
CADL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, COR currently ranks higher by quality score.
| CADL | COR | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $8.19 | $323.85 |
| 12-month range | $4.42–$13.75 | $252.74–$374.75 |
| Rank by discount to fair value | — | #58 of 108 Healthcare |
| Rank by quality score | #283 of 301 Healthcare | #282 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | High |
| Margin trend | Contracting | Stable |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Overbought |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: CADL fair value analysis · COR fair value analysis